Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

[1]  Paola Guglielmelli,et al.  JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.

[2]  R. Mesa,et al.  Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis. , 2007 .

[3]  D. Gary Gilliland,et al.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders , 2007, Nature Reviews Cancer.

[4]  D. Gilliland,et al.  Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes , 2007, Stem cells.

[5]  R. Mesa,et al.  A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia , 2007, Leukemia.

[6]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[7]  D. Gilliland,et al.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.

[8]  W. Vainchenker,et al.  The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. , 2007, Blood.

[9]  Paola Guglielmelli,et al.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.

[10]  D. Carbone,et al.  Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. , 2007, Blood.

[11]  T. Barbui,et al.  Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.

[12]  A. Tefferi,et al.  Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera , 2007, Leukemia.

[13]  A. Tefferi,et al.  Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.

[14]  A. Tefferi,et al.  Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera , 2007, Leukemia.

[15]  A. Tefferi,et al.  JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder , 2007, Leukemia.

[16]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[17]  R. Levine,et al.  Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time , 2006, British journal of haematology.

[18]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[19]  P. Campbell,et al.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.

[20]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[21]  D. Steensma,et al.  JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained , 2006, Leukemia.

[22]  M. Calasanz,et al.  JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients , 2006, Leukemia.

[23]  P. Campbell,et al.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.

[24]  M. Wadleigh,et al.  The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera , 2006, Cancer.

[25]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[26]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[27]  P. Guglielmelli,et al.  Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.

[28]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.

[29]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[30]  R. McClure,et al.  Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders , 2006, Leukemia.

[31]  B. Woda,et al.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features , 2006, Leukemia.

[32]  R. Levine,et al.  The JAK 2 V 617 F activating tyrosine kinase mutation is an infrequent event in both “ atypical ” myeloproliferative disorders and myelodysplastic syndromes , 2005 .